Zacks Research Has Pessimistic Outlook of Sanofi Q4 Earnings

Sanofi (NASDAQ:SNY - Free Report) - Analysts at Zacks Research lowered their Q4 2025 earnings estimates for Sanofi in a note issued to investors on Tuesday, October 15th. Zacks Research analyst K. Shah now forecasts that the company will earn $1.23 per share for the quarter, down from their prior forecast of $1.24. The consensus estimate for Sanofi's current full-year earnings is $4.26 per share. Zacks Research also issued estimates for Sanofi's Q3 2026 earnings at $1.35 EPS.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.05. The firm had revenue of $10.75 billion during the quarter, compared to analysts' expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company's revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.95 EPS.

A number of other brokerages have also recently weighed in on SNY. Argus upped their price objective on Sanofi from $55.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, July 26th. Citigroup raised shares of Sanofi to a "strong-buy" rating in a research report on Tuesday, September 17th. Finally, StockNews.com downgraded shares of Sanofi from a "strong-buy" rating to a "buy" rating in a research report on Monday. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $57.50.

Sanofi Stock Up 0.1 %

Sanofi stock traded up $0.07 during mid-day trading on Friday, reaching $54.93. 1,195,850 shares of the company were exchanged, compared to its average volume of 2,019,651. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market cap of $139.12 billion, a P/E ratio of 27.60, a PEG ratio of 1.57 and a beta of 0.60. The business has a fifty day moving average of $56.11 and a 200 day moving average of $51.53. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97.

Institutional Investors Weigh In On Sanofi

Several institutional investors have recently added to or reduced their stakes in the business. EP Wealth Advisors LLC grew its holdings in shares of Sanofi by 5.3% during the fourth quarter. EP Wealth Advisors LLC now owns 5,035 shares of the company's stock valued at $250,000 after buying an additional 255 shares during the last quarter. HighPoint Advisor Group LLC acquired a new stake in Sanofi during the 4th quarter valued at approximately $338,000. GAMMA Investing LLC lifted its stake in Sanofi by 30.5% during the 1st quarter. GAMMA Investing LLC now owns 2,119 shares of the company's stock valued at $103,000 after acquiring an additional 495 shares during the period. Alaska Permanent Fund Corp acquired a new stake in shares of Sanofi in the first quarter worth $237,000. Finally, Lantz Financial LLC raised its holdings in shares of Sanofi by 33.3% during the first quarter. Lantz Financial LLC now owns 6,536 shares of the company's stock worth $318,000 after purchasing an additional 1,633 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company's stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.